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SUMMARY. In a retrospective study, the results after resection of carcinoma of the gastric cardia in the era
without neoadjuvant therapy or extended lymph node dissection were evaluated. All 184 patients who underwent
resection between January 1983 and December 1993 were included. Recurrence of disease, survival and prognostic
factors were determined. The overall cumulative 5-year recurrence rate was 71% and the survival rate 23%.
Multivariate analysis identified locoregional lymph node and distant metastases as the crucial prognosticators of
recurrence of disease and survival. These results were similar to those from a previous study concerning our patients
operated during the years 1983–88. The prognosis of a resected cardiacarcinoma has remained unchanged in our
hands over the past 10 years. These results stress the importance of exploring new ways, such as the use of new
diagnostic tools, to optimize preoperative patient selection and more aggressive treatment regimens to improve final
outcome.
INTRODUCTION
Treatment of adenocarcinoma of the gastric cardia
carries poor survival rates. Metastatic disease is
present in many patients at the time of diagnosis of
the disease. Nevertheless, even when the patient
cannot be cured, resection is often considered the
most eective means of palliation.
Previously, we reported in a smaller series on the
outcome after resection of carcinoma of the gastric
cardia.1 We decided to evaluate the data of all
patients that had been operated on for this disease in
the decade before the introduction of novel treatment
options such as neoadjuvant therapy and extended
lymph node dissection to detect any improvements in
outcome compared with the previous report. If
present, such improvements should mainly be attrib-
uted to advances in perioperative care. If not, this
would be a strong argument in favor of exploring new
ways of patient selection and treatment, using new
diagnostic and therapeutic options.
Also, in the present study, an analysis was
performed to identify independent factors influencing
outcome after surgery. Such factors should be looked
for in the preoperative work-up in an attempt to
tailor the treatment to the patient.
PATIENTS AND METHODS
A tumor was defined as an adenocarcinoma of the
gastric cardia when it was confined to the cardia,
when it was located in the fundus of the stomach and
had reached the cardia, or when such tumor had
crossed over to the distal esophagus. By definition,
carcinoma arising in Barrett’s esophagus was not
included.2 By some, the last carcinoma is considered
clinically and epidemiologically a separate entity.3
Between 1 January 1983 and 31 December 1993,
184 patients underwent resection of their cardia
carcinoma at the Department of General Surgery,
Erasmus University Hospital, Rotterdam, The Neth-
erlands. For this study, the information of the
database of the Rotterdam Esophageal Tumor Study
Group was used. In the same period, in 38 additional
cases, resection was not performed because of the
presence of metastatic lymph nodes at the celiac axis
(22 cases), peritoneal metastases (14 patients), or liver
metastases (two cases). These patients were excluded
from the study.
In 177 patients, partial or subtotal esophagectomy
was performed: in 133 with removal of the cardia and
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in 44 with removal of the entire stomach. In seven
cases, resection was limited to a total gastrectomy.
Before 1987, esophagectomy was performed by
laparotomy and separate thoracotomy with an intra-
thoracic anastomosis. Thereafter, the transhiatal
approach with blunt dissection of the upper two-
thirds of the esophagus and a cervical esophagogas-
trostomy with creation of a stomach tube has been
preferred.4 Perigastric lymph nodes and those around
the distal esophagus and celiac axis were removed.
No extended lymph node dissection was performed.
Some of our patients received radiotherapy.
Before 1987, preoperative radiation therapy was
given in our institution by protocol to patients with
tumor invasion of the esophagus. This included 43
patients of the present series. This policy was based
on studies in which a combined modality treatment
strategy of preoperative radiation therapy and sur-
gery was used for patients with esophageal cancer,
suggesting superiority to surgery alone.5,6 Until 1987,
post-operative radiation therapy was administered to
patients with a T3 or T4 tumor status and patients
with positive lymph nodes or residual tumor at the
resection margins. Later prospective studies showed
no beneficial eects of pre- or post-operative radia-
tion therapy on recurrence of disease or on survival
after resection of a carcinoma of the esophagus or the
cardia.7–9 Therefore, after 1986, only selected patients
in whom a macroscopically irradical resection was
performed underwent post-operative radiation.
Post-operative histologic tumor classification was
performed according to the TNM criteria for
carcinoma of the stomach as established by the
International Union Against Cancer/American
Joint Committee on Cancer10 (Tables 1 and 2). In
this system, positive lymph nodes around the
stomach or the distal intra-abdominal esophagus
and within 3 cm of the tumor are classified as N1
nodes. N2 lymph nodes are situated perigastric, but
more than 3 cm from the tumor, or around the
celiac trunk, left gastric artery, splenic artery or
common hepatic artery. Para-aortic and para-
esophageal lymph nodes and those along the proper
hepatic artery or in the splenic hilus are considered
to be distant metastases.
Both locoregional recurrences and distant metas-
tases were considered manifestations of recurrent
disease. Survival rates and rates of recurrence were
calculated on an actuarial basis with the Kaplan–
Meier method. Comparison between these curves was
made with the use of the log-rank test. Multivariate
Cox regression analysis was carried out to identify
independent prognostic factors. Intercurrent death-
corrected survival was calculated by considering the
patients who died of causes unrelated to their
carcinoma as having been withdrawn from the study
at the date of death; p  0.05 (two-sided) was
considered the limit of significance. Patient follow-up
was complete.
RESULTS
Of the 184 patients in this study, 157 were men and 27
women, with a mean age at operation of 62 years
(range 35–85). Average length of follow-up was
26 months.
The distribution according to the subclasses of the
postoperative TNM staging system is given in
Table 2.
Table 1. Stage of disease according to the 1992 pTNM classifica-
tion of stomach carcinoma
IA T1N0M0
IB T1N1M0, T2N0M0
II T1N2M0, T2N1M0, T3N0M0
IIIA T2N2M0, T3N1M0, T4N0M0
IIIB T3N2M0, T4N1M0
IV T4N2M0, TxNxM1
Fig. 1—Kaplan–Meier curves representing cumulative recurrence-
free survival rates after resection of adenocarcinoma of the gastric
cardia. Percentages (actuarial) without recurrence according to (A)
N-category and (B) M-category. Percentages at 1, 2, 3, 4 and
5 years for the total study group are, respectively, 59%, 42%, 33%,
29% and 29%.
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Recurrence
Recurrence of disease was found in 102 patients.
All recurrences appeared within 4.5 years after
operation. No dierence in recurrence rate was
observed between the dierent levels of tumor
penetration (T-stage, Table 2). The recurrence rate
was significantly higher in the presence of positive
locoregional lymph nodes than when these were
absent (p < 0.001, Fig. 1A). No dierence was
observed between positive nodes at the N1 or N2
location. None of the patients with metastases
remained free of disease compared with 32% of
those without (p < 0.001, Fig. 1B). With decreas-
ing grade of radicality of resection, with decreasing
grade of dierentiation of the tumor or with
increasing TNM stage, a trend towards a higher
recurrence rate was observed.
Survival
The in-hospital mortality rate was 4.3% (eight
patients). Of our study group, 121 patients died
during follow-up, of whom only 14 without evidence
of recurrent disease. The overall 5-year survival rate
was 23%. This diered only slightly from the
intercurrent death-corrected rate of 27%, indicating
that only few patients died without prior recurrence
of disease.
Five-year survival in relation to the TNM classi-
fication was as follows (Table 2): no dierence was
observed between the dierent T-stages; 38% of the
patients without involvement of the lymph nodes
survived 5 years compared with 15% with positive
nodes (N1 or N2) (p < 0.001, Fig. 2A); 25% of the
patients without metastases were alive after 5 years,
but none of those in whom metastases were present
(p < 0.001, Fig. 2B). The median survival for
patients with N0 nodal status was 30 months com-
pared with 12 months for those with N1 or N2 status;
these figures were 18 and 9 months in cases of a M0
and M1 classification respectively.
As with recurrence of disease, there was a trend
towards increasing survival with increasing TNM
stage (p < 0.001). The same trend was observed with
decreasing histopathologic grade of dierentiation
and decreasing radicality of the operation.
Multivariate analysis
T-, N- and M-category, histopathologic grade, rad-
icality of resection, sex and age were independently
evaluated in a multivariate analysis. N- and
M-category were both significantly related to recur-
rence and survival (Table 3). Male sex and older age
were also identified as risk factors for death.
DISCUSSION
‘No news’: perhaps this should be the rather
disappointing message from the present study.
Table 2. Recurrence and survival rates after resection of adenocarcinoma of the gastric cardia
TNM* Number
Recurrence  Survival
subclasses of patients 2 year (%) 5 year (%) p-value 2 year (%) 5 year (%) p-value
T1 8 56 (2) 56 (2) 54 (3) 36 (2)
T2 36 47 (12) 70 (4) 0.46 65 (15) 25 (4) 0.37
T3 136 61 (37) 73 (13) 40 (45) 21 (13)
T4 4 67 (1) 67 (1) 25 (1) 25 (1)
N0 74 33 (36) 52 (15) <0.001 69 (41) 38 (15) <0.001
N1/2 110 77 (16) 85 (5) 27 (23) 15 (5)
M0 171 55 (51) 68 (20) <0.001 48 (63) 25 (20) <0.005
M1 13 92 (1) 100 (0) 8 (1) 0 (0)
R0 149 54 (46) 69 (19) 0.03 49 (57) 25 (19) 0.02
R1 31 73 (6) 82 (1) (trend) 28 (7) 16 (1) (trend)
R2 4 100 (0) 100 (0) 0 (0) 0 (0)
G1 5 0 (4) 50 (2) 100 (4) 50 (2)
G2 64 49 (23) 76 (5) 0.07 54 (28) 18 (5) 0.09
G3 105 65 (23) 71 (12) (trend) 38 (30) 24 (12) (trend)
G4 10 73 (2) 73 (1) 23 (2) 23 (1)
Stage
IA 8 56 (2) 56 (2) 54 (3) 35 (2)
IB 18 26 (10) 61 (3) 88 (12) 32 (3)
II 52 34 (25) 50 (10) <0.001 64 (28) 38 (10) <0.001
IIIA 57 79 (8) 85 (4) (trend) 32 (14) 13 (4) (trend)
IIIB 35 67 (6) 74 (1) 25 (6) 25 (1)
IV 14 93 (1) 100 (0) 7 (1) 0 (0)
*Defined according to the criteria for carcinoma of the stomach as established by the International Union Against Cancer/American Joint
Committee on Cancer.10
 Cumulative (actuarial) percentage.
p-values from log-rank test. Numbers in parentheses give numbers of patients at risk after 2 and 5 years.
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The recurrence and survival rates are unchanged
compared with an earlier series at our institute
comprising patients operated during the years 1983
to 1988.1 Nor are they essentially better than those
reported in earlier series from other authors. In
these studies on resected adenocarcinoma of the
gastric cardia or gastroesophageal junction, the
5-year survival rates after resection ranged from
10% to 29%.11–15
Lymph node involvement and the presence of
distant metastases were identified in multivariate
analysis as independent factors influencing recurrence
of disease and survival. This is a common finding in
other series, concerning patients with cardia-
carcinoma,11 esophageal carcinoma16,17 or both.18–20
In these series, 5-year survival rates of patients with
negative nodes ranged from 36% to 58%, compared
with 38% in the present series.
Because of a growing interest in lymph node
dissection and the expectation that the presence of
positive nodes at the N2 location would carry a worse
prognosis than cases with positive N1 nodes, the
results were analyzed according to lymph node status.
No dierence in recurrence or survival rates could be
demonstrated between N1 or N2 positive nodes. We
should realize, however, that this apparent absence of
dierence might be due to the fact that no true
extended lymph node dissection was carried out. As a
result of this, the N-classification was probably not
entirely accurate.
The predominance of men and age distribution
correlate with other series data.18,21 In our series, a
better prognosis for women is observed. This corres-
ponds to the findings of a large Japanese series on
esophageal and cardia carcinoma.19 This phenom-
enon cannot be confirmed by other series.16,22,23 Its
relevance therefore remains uncertain.
In general, we consider the presence of metastases
a contraindication for resection. Nevertheless, 13
patients classified in the pTNM staging as having
distant metastases underwent resection. Most of these
metastases were lymph nodes that were discovered
when a considerable part of the resection had already
been carried out, or that were found post-operatively
in the resection specimen. However, in four cases,
metastases were apparent at an early stage of the
operation. Resection was nevertheless carried out, as
it was considered the best palliation in these patients
with the combination of invalidating dysphagia,
relatively young age and good physical condition.
Fig. 2—Kaplan–Meier curves representing cumulative survival
rates after resection of adenocarcinoma of the gastric cardia.
Survival according to (A) N-category and (B) M-category. Survival
percentages at 1, 2, 3, 4 and 5 years for the total study group are,
respectively, 69%, 44%, 31%, 27% and 23%.
Table 3. Multivariate analysis of factors predicting recurrence or
death after resection of adenocarcinoma of the gastric cardia
Prognostic factor Relative risk (RR) p-value
Recurrence
Nodal status
N0 1
N1 2.4 <0.001
N2 3.0 <0.001
Metastases
M0 1
M1 2.0 0.03
Sex
Male 1
Female 0.6 0.08
Survival
Nodal status
N0 1
N1 2.2 <0.001
N2 2.7 <0.001
Metastases
M0 1
M1 2.2 0.02
Histologic grade 1.4* 0.04 (trend)
Sex
Male 1
Female 0.5 0.01
Age
<56 years 1
56–69 years 1.6 0.05
>69 years 2.1 0.01
Reference categories are indicated by RR = 1. p-values refer to
comparisons with the reference categories.
*Compared with one histologic grade higher.
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What, then, is new? Do options exist to improve
the future outcome after resection of a cardia-
carcinoma?
Many eorts are put into optimizing preoperative
tumor staging. Proper preoperative patient selection
enables us to give the best treatment to each patient.
Of special importance is the detection of metastases
or positive lymph nodes and of a locally irresectable
tumor. The presence of distant metastases is generally
believed to be a contraindication for resection.
Preoperative finding of this condition or of a locally
irresectable tumor would avoid an unnecessary
laparotomy. Renewed attention has been focused
on the identification of suspect locoregional nodes. It
has been suggested that patients with a gastric
carcinoma and positive nodes might benefit from an
extended lymphadenectomy.24 If this is confirmed by
future studies, preoperative identification could result
in a policy of extended dissection in these selected
cases.
In the past decade, several new diagnostic tools
have been proven eective in enhancing the accuracy
of preoperative staging, such as endoscopic ultra-
sonography (EUS) and laparoscopy combined with
laparoscopic ultrasound (LUS). In diagnosing the T
and N classification, EUS is superior to conventional
staging by abdominal ultrasound or computed tomog-
raphy (CT) scanning.25–27 The sensitivity and speci-
ficity of EUS in detecting locoregional lymph node
involvement range from 75% to 85% and from 70%
to 88% respectively.26,28,29 A novel approach is the
use of a curved-array echoendoscope.30 This facili-
tates EUS-guided biopsies of suspected lesions be-
cause the full length of the needle can be visualized.
For detecting distant lymph node metastases such
as those at the celiac axis, CT scanning remains
superior to EUS.31 Van Overhagen et al.32 found that
these metastases and those in the supraclavicular
region can be equally accurately assessed by conven-
tional ultrasound or CT.
The value of laparoscopy, combined with lap-
aroscopic ultrasound (LUS), lies in visualization of
small intra-abdominal or peritoneal lesions and in
improved detection of liver metastases, direct tumor
extension and lymph node metastases in the retro-
peritoneum. Laparoscopy is more sensitive and
accurate than ultrasonography and CT scanning with
regard to evaluation of the hepatic status in patients
with esophageal and cardia cancer.33 It is also
superior to conventional ultrasound in detecting
intra-abdominal metastases and superior to CT and
ultrasound in detecting peritoneal lesions.27,33 In a
series on esophageal and cardia carcinoma, 38 out of
179 patients with a normal or equivocal ultrasound
(US) or CT were found to have intra-abdominal
tumor spread at laparoscopy that prohibited resec-
tion.34 In a recent series, LUS provided a better
N-and M-staging than CT or endoscopic ultrasonog-
raphy. The authors stress the importance of adequate
staging to improve selection for operation or inclu-
sion in neoadjuvant chemotherapy trials.35
Evidently, preoperative tumor staging has
improved. This alone will not improve the outlook
for our patients, but it enables us better to select
patients for new therapeutic options.
One of the developments that seems of interest for
patients with a cardiacarcinoma is neoadjuvant
therapy. Concomitant preoperative radiotherapy
and chemotherapy or pre- and post-operative che-
motherapy can be considered neoadjuvant. Unfortu-
nately, no reports have been published yet of its use
in patients with a cardiacarcinoma. Promising data,
however, are available on the combination of preop-
erative radiotherapy and chemotherapy for esopha-
geal cancer. Leichman et al.36 took the lead by
publishing the concept in 1984. Since then, several
groups have published their results using this treat-
ment in both adenocarcinoma and squamous cell
carcinoma of the esophagus.37–39 The majority of
these trials report a survival advantage of the therapy
group over controls. Comparison between studies is
dicult because of dierences in preoperative sta-
ging, drugs used and estimation of response. Never-
theless, especially the observation that in a subset of
patients complete disappearance of the tumor occurs,
which is associated with a substantial survival benefit,
is intriguing.38–40 The feasibility of disease control
and downstaging is currently being assessed for
gastric cancer in the large Medical Research Council
MAGIC (pre- and post-operative gastric infusional
chemotherapy) Trial.
Another concept that might prove to be of benefit
for our patients is extended lymph node dissection.
Until now, it is theoretically promising, but its impact
in the treatment of gastroesophageal cancer still has
to be established. Favorable reports from Japan are
well known, yet even from this country the question is
raised as to whether extended lymph node dissection
is truly of therapeutic benefit or merely represents a
staging procedure.41 Of course, more accurate staging
is of great importance. Not only by enhancing the
comparability of studies, but also by revealing
dierences in survival or recurrence that would have
remained unnoticed with less secure staging (for
example, a survival dierence between N1 and N2
node-positive patients). Averbach and Jacquet24 sug-
gest that in stages II and IIIA gastric cancer a
therapeutic advantage of extended (D2) dissection
can be expected as the resection line in such dissection
encompasses the N2 lymph nodes. Especially when
these are free of tumor, the margin of resection is
improved. On the contrary, in a limited (D1,
perigastric nodes only) lymph node dissection, the
resection is carried out through tissue harboring
cancer in half of the patients.42 Nevertheless, the
problem of increased post-operative morbidity and
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mortality has not yet been solved, thereby remaining
an important argument against extended lymph-
adenectomy.
Finally, also concerning the possible prevention of
gastric and cardia carcinoma, intriguing knowledge is
emerging. This is the possible relation between
Helicobacter pylori infection and gastric cancer that
should not remain unmentioned. McFarlane and
Munro43 comprehensively summarized the possible
sequence from H. pylori infection to the development
of gastric carcinoma. The majority of patients
infected will remain asymptomatic with chronic
active gastritis. A minority will progress to atrophic
gastritis, which can subsequently lead to intestinal
metaplasia, dysplasia and cancer. What determines
which route the infection in the individual will follow
is yet to be determined. The strain of H. pylori, the
age at acquisition of the infection and genetic and
environmental factors probably all play a role. The
unraveling of the sequence after infection and the
influence of other factors thereupon may contribute
to the prevention of gastric carcinoma.
In conclusion, the results of the present series
compared with a previous series of our institute
illustrate that the prognosis of our patients after
resection of adenocarcinoma of the gastric cardia has
remained unchanged over the past decade. This
disappointing message emphasizes the importance
of exploring new ways to improve these results.
Enhancing the accuracy of preoperative tumor sta-
ging in combination with the application of new
treatment regimes such as neoadjuvant therapy and
extended dissection in selected patients might
improve the outlook after resection of this disease.
In order to define the exact value of such new
treatment regimes, participation in prospective ran-
domized studies, of which several are already under
way, is mandatory.
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